Moderna RSV Vaccine Gets Expanded FDA Approval, Company Says

Published: 2025-06-12 20:06:08 ET MRNA

Published on 06/12/2025 at 20:06

By Daniel Papp

Moderna said the Food and Drug Administration expanded its approval of the pharmaceutical company's respiratory syncytial virus vaccine, mResvia, to adults aged 18-59 at increased risk for the disease.

The agency's approval was supported by results from a trial which evaluated the safety and immunogenicity among at-risk adults within the specified age range, Moderna said Thursday. The study found immune responses from mResvia against RSV-A and RSV-B met prespecified criteria. It was also generally well tolerated, according to the Cambridge, Mass., company.

The findings were presented at the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices meeting in April.

The FDA previously approved mResvia for adults aged 60 years and older in May 2024.

Write to Daniel Papp at [email protected]

(END) Dow Jones Newswires

06-12-25 2006ET